GenSpera gets Grebow on board
This article was originally published in Scrip
Executive Summary
GenSpera, a development-stage oncology company, has appointed Dr Peter Grebow to its board of directors. Dr Grebow has 37 years' experience in the pharmaceutical industry having served at Cephalon from 1991-2011, most recently as executive vice-president of technical operations. He is now president of P.E. Grebow Consulting, which he founded in 2011, and a director of both Optimer Pharmaceuticals and Q Holdings.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.